v-Several investigators have detected progesterone receptors in a high percentage of meningioma specimens and have noted progesterone receptors to be more common than estrogen receptors in these specimens. However, a functional significance of such hormone receptor positivity in control of meningioma growth has not been described. This paper describes a paired test of the estrogen and progesterone receptor assay as the biochemical assay and of the human tumor stem-cell clonogenic assay (HTSCCA) as the functional assay in 17 meningioma specimens. Only one (6 %) of the 17 specimens was estrogen receptor-positive, while 11 (69 %) of 16 specimens were progesterone receptor-positive. The HTSCCA revealed that only two (15%) of 13 specimens were sensitive to estradiol while five (31%) of 16 specimens were sensitive to progesterone. Comparison of progesterone results for the 15 specimens on which both hormone receptor assay and HTSCCA were performed revealed correlation in a majority of cases; four specimens were positive for both assays and five specimens were negative for both assays. No specimen that was negative for progesterone receptors was sensitive to progesterone by HTSCCA. These results suggest that the hormone receptor and sensitivity pattern of meningiomas may differ from that of breast cancer, and that progesterone addition or ablation may be a reasonable therapeutic approach for meningiomas. KEY WORDS 9 meningioma 9 progesterone receptor 9 estrogen receptor brain neoplasm 9 tissue culture S
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EVERAL lines of evidence have suggested that the growth of meningiomas may be related to steroid hormones. The incidence of meningiomas is twice as high in women as in men, 12 and increased growth of these tumors has been described during pregnancy. 2 In addition, two large epidemiological studies have demonstrated a significantly increased risk of meningioma in patients with breast cancer. Schoenberg, The present study was therefore designed to perform paired testing for a biochemical marker (hormone receptor) and a functional assay measuring the effect of human tumor stem-cell clonogenic assay; ER = PR = progesterone receptor; --= assay not perestradiol and progesterone in pharmacological concentrations on meningioma growth (human tumor stemcell cionogenic assay, or HTSCCA).
Materials and Methods

Procurement of Specimens
At the time of surgery for meningioma, tumor specimens were obtained for hormone receptor assay and for HTSCCA. Specimens for hormone receptor assay were immediately frozen in liquid nitrogen. Specimens for HTSCCA were immediately placed in transport medium consisting of lactated Ringer's solution with gentamicin and HEPES buffer. Pathological confirmation of meningioma was obtained in all cases.
Hormone Receptor Assay Methodology
A modified dextran-coated charcoal method was used for the hormone receptor assay. Tissues were minced and placed into 10 mM phosphate, 10% glycerol, 1 mM ethylenediaminetetra-acetic acid (EDTA), and 1 mM dithiothreitol buffer, pH 7.4. The tissue was then homogenized on ice in a polytron device* using three bursts for a 5-second duration. Homogenates were spun at 100,000 G for 45 minutes. Supernatants were adjusted to a protein concentration of 2 mg/ml for ER assays and 4 mg/ml for PR assays. A 0.2-ml aliquot of cytosol was incubated overnight with 0.05 ml tritiated (3H)-estradiol and progesterone-17-methyl-3H (R5020) at six standard concentrations at 4~ Nonspecific * Polytron homogenizer, Model pI0-ST, manufactured by Brinkmann Instruments Co., Westbury, New York.
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binding was assessed with 200-fold molar excess of diethylstilbestrol (DES) and R5020 for ER and PR, respectively. Bound hormone was separated from free hormone by incubation with 0.5 ml of dextran (2.5%)/ charcoal (0.25%) for 20 minutes, followed by centrifugation at 2000 G for 5 minutes. Radioactivity was determined in a 0.5-ml aliquot of supernatant for 10 minutes. Assays were performed in duplicate when sufficient material was available. Dissociation constant (Ka) and maximum binding (Bmax) were calculated according to the method of Scatchard? 3
HTSCCA Methodology
For HTSCCA, meningioma specimens were minced in McCoy's 5A medium with 50 U penicillin/ml, 50 ug streptomycin/ml, 20 mM HEPES buffer, and 24 mM NaHCO3, pH 7.4. Collagenase (Worthington Type III) was added to obtain a final concentration of 0.2 mg/ ml. Specimens were dispersed by fluid shear forces and then sequentially forced through 20-and 200-urn mesh stainless steel screens. Cells collected by centrifugation (900 G for 5 minutes) were resuspended in McCoy's 5A medium with 6% heat-inactivated calf serum at a concentration of 107 nucleated cells/ml solution. Progesterone (pregnene-3,20-dione) and estradiol (B-estradiol-diacetate)? were diluted with ethanol to a concentration of 100 ug/ml and passed through a 0.22-u filter. Test doses were dispensed and stored at -45~ Cells in aliquots of 0.125 ml were exposed to drug at 0.1 and 10 ug/ml for 1 hour at 370C. Following incubation, cells were plated with enriched McCoy's 5A overlayer medium and agar.
Cultures were incubated at 37~ for 10 to 14 days. Colonies (compact groups of cells at least 50 u in diameter containing at least 30 cells) were counted using an inverted microscope, and data were expressed as percent of colony formation observed in control plates.
Definition of Responses
A hormone receptor value of 5 fM/mg was considered to be a positive hormone receptor assay response. Survival of 30% or less of the colonies as compared to control was considered to be a positive HTSCCA response.
Results
Specimens were obtained from 17 patients. Twelve of the patients were female and five were male. The diagnosis of meningioma was pathologically confirmed in all cases; five tumors were further subclassified as fibrous meningioma, three as meningiotheliomatous meningioma, and two as containing both fibrous and meningiotheliomatous areas. One patient had a spinal meningioma. None of the patients had received radiation therapy or chemotherapy prior to surgery. * HTSCCA = human tumor stem-cell clonogenic assay.
Hormone Receptor Assay
Specimens from all 17 cases were submitted for hormone receptor assays (Table 1 ). An ER assay was performed for all specimens and a PR assay was performed for all specimens but one. The ER assay was positive in only one (6%) of the 17 patients: in this case the assay was only weakly positive, with a value of 7 fM/mg. The PR assay was positive in 11 (69%) of 16 patients. Eight of these patients had values over 40 fM/ mg and two had values over 100 fM/mg. The dissociation constant (K~) for 10 of the 11 patients with positive PR assays fell between 0.2 • 10 -9 M and 1.5 • 10 -9 M.
Human Tumor Stem Cell Clonogenic Assay
Specimens from all 17 cases were submitted for HTSCCA (Table 1) . In 16 cases, colony growth was observed and assays could be performed. In 13 of these cases, HTSCCA was performed for both estrogen and progesterone. In three cases, sufficient material was obtained for only one hormone assay and HTSCCA for progesterone was performed.
In 14 of 16 progesterone assays and 11 of 13 estrogen assays, a greater effect was seen at the higher drug dose (10 #g/ml). In the remaining four assays, results were equivalent, with colony survival at the two doses (0.1 and 10 ug/ml) differing by no more than 8%. The HTSCCA results from the 10-#g/ml drug dose were therefore used for analysis. The HTSCCA revealed that the meningioma specimen was sensitive to estradiol in only two (15%) of the 13 specimens. None of these specimens showed sensitivity to tamoxifen (unpublished data, 1986). However, significant growth suppression by progesterone was observed in five (31%) of 16 cases.
Correlation of Assays
Results of the hormone receptor assay and HTSCCA were compared for specimens in which both studies were obtained (Table 2 ). In 13 cases, both the ER assay and HTSCCA for estradiol were performed. However, in a majority of these cases (77%) both the ER assay and the HTSCCA for estradiol were negative, giving the assays little predictive value.
In 15 cases, both the PR assay and the HTSCCA for progesterone were performed. In a majority of these cases there was a correlation between results of the two assays. Four patients were both PR-positive and sensitive to HTSCCA growth suppression by progesterone. Five patients were PR-negative and resistant to HTSCCA growth suppression with progesterone. Progesterone receptor positivity was also noted to have a 40% positive predictive value (four of 10 PR-positive patients were sensitive to HTSCCA growth suppression by progesterone).
Discussion
Our study confirms previous observations that have suggested that PR positivity is more common than ER positivity in cases of meningioma. 3,1~
The classic oncological model for estrogen and progesterone receptors is that of breast cancer, in which PR's are considered to be induced by nuclear translocation of estrogen/ER complexes. 7 Since the production of PR's depends upon functioning ER's, most specimens that are PR-positive are also ER-positive. The preponderance of PR positivity in cases of meningioma has therefore led to some question concerning the nature of the progesterone-binding protein. Schwartz, et al., 16 suggested that this protein does not have the competitive binding specificity necessary for definition as a receptor. However, several other studies 3,2~ have shown that the requisite binding specificity characteristics for a true PR are indeed found in patients with meningioma. Our data also indicate that the dissociation constant (Ka) of the putative meningioma PR is consistent with a classic hormone receptor. In addition, the breast cancer cell line T47D has been described to have extremely high PR levels with minimal ER levels) Characterization of this cell line demonstrates that it is indeed possible for the PR system to become dissociated from and operate independently of the ER system. Few studies have examined the effect of hormonal manipulations on meningioma growth. Jay, et al., 9 utilized a cell growth assay and reported a mild antagonistic effect of physiological concentrations of estradiol and progesterone on meningioma growth. We have used the HTSCCA in an attempt to demonstrate growth suppression of greater magnitude induced by pharmacological levels of hormone. The low level of activity of estradiol and lack of activity of tamoxifen at these concentrations are consistent with the low level of ER positivity. However, the possibility of progesteroneinduced modulation of meningioma growth is intriguing. The clinical experience with breast cancer has shown that receptor positivity will predict clinical efficacy of hormone modulation in approximately 50% of cases, and that both hormone supplementation and hormone ablation may be of value as therapeutic maneuvers. 6 Our study indicates that a significant number of meningioma specimens in tissue culture will demonstrate growth suppression by pharmacological levels of progesterone and that PR positivity is predictive of such an effect in approximately 40% of cases.
Due to the dependence of the PR system on the ER system in breast cancer, much of the emphasis of recent breast cancer hormonal therapy has been focused on modulation of effective estrogen levels, particularly utilizing the anti-estrogen drug, tamoxifen. 6 However, tissue culture studies with the T47D and MCF7 PRpositive breast cancer cell lines indicate that growth of such lines may be specifically suppressed with RU486, a potent anti-progestin agent? In a system such as meningioma where PR's seem to predominate, modulation of progesterone levels with either progestin agonists or antagonists may hold greater therapeutic promise.
